Fusion Antibodies Plc (GB:FAB) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Fusion Antibodies Plc has secured a contract to develop a therapeutic antibody to combat a chronic disease, expecting to generate £200,000 in revenue within the current financial year, along with future royalties from commercial sales. The company continues to leverage its expertise in antibody engineering, working closely with a long-standing US biotech client, with whom they have an ongoing $650,000 project. Fusion Antibodies’ growth strategy focuses on accelerating the drug development process for pharmaceutical and diagnostic companies.
For further insights into GB:FAB stock, check out TipRanks’ Stock Analysis page.